The Aliso Viejo, Calif.–based company raised the money from 18 investors, according to an SEC Form D filed June 10.
After securing FDA clearance in late 2019, Okami Medical announced the first use of LOBO on a patient in March. The LOBO (Low-Profile Braided Occluder ) system’s creators designed it to provide interventional physicians with a single-device, one-and-done solution for the occlusion of various arterial targets without the need for multiple embolic devices.
The system’s HDBraid technology is meant to create a highly occlusive pore structure to substantially reduces blood flow and accelerate vessel closure. The LOBO-3 occluder is meant for use in 1.5 to 3 mm diameter vessels.
The low-profile embolic device features a microcatheter to provide smooth peripheral vasculature navigation. When deployed, the occluder self-expands, conforming to a range of targets such as curved vessels.